FY2025 EPS Estimates for Shattuck Labs, Inc. Lowered by HC Wainwright (NASDAQ:STTK)

Shattuck Labs, Inc. (NASDAQ:STTK) – Equities researchers at HC Wainwright cut their FY2025 EPS estimates for shares of Shattuck Labs in a report released on Wednesday, April 10th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($2.00) for the year, down from their previous estimate of ($1.95). HC Wainwright has a “Buy” rating and a $28.00 price target on the stock. The consensus estimate for Shattuck Labs’ current full-year earnings is ($1.85) per share.

Shattuck Labs (NASDAQ:STTK) last issued its quarterly earnings data on Thursday, February 29th. The company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.10. Shattuck Labs had a negative return on equity of 63.08% and a negative net margin of 5,268.44%. The business had revenue of $0.71 million during the quarter, compared to analysts’ expectations of $0.50 million.

Separately, Needham & Company LLC reissued a “buy” rating and issued a $12.00 price objective on shares of Shattuck Labs in a research note on Tuesday, April 9th.

Shattuck Labs Price Performance

NASDAQ STTK opened at $9.09 on Monday. The company has a market cap of $431.50 million, a P/E ratio of -4.43 and a beta of 2.11. The stock has a 50-day moving average of $9.14 and a two-hundred day moving average of $6.17. Shattuck Labs has a 1-year low of $1.33 and a 1-year high of $11.11.

Institutional Trading of Shattuck Labs

A number of large investors have recently made changes to their positions in the company. Squarepoint Ops LLC acquired a new position in Shattuck Labs during the 1st quarter worth approximately $30,000. UBS Group AG grew its stake in shares of Shattuck Labs by 62.3% during the first quarter. UBS Group AG now owns 10,978 shares of the company’s stock worth $32,000 after purchasing an additional 4,214 shares in the last quarter. Balyasny Asset Management LLC acquired a new position in shares of Shattuck Labs during the third quarter worth $35,000. Acadian Asset Management LLC purchased a new position in Shattuck Labs in the first quarter valued at $37,000. Finally, Jane Street Group LLC acquired a new stake in Shattuck Labs in the first quarter valued at $58,000. 58.74% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Shattuck Labs

In related news, insider Stephen Stout sold 16,004 shares of Shattuck Labs stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $10.53, for a total value of $168,522.12. Following the completion of the transaction, the insider now directly owns 74,437 shares in the company, valued at $783,821.61. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 9.46% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.